Searching for the press releases
List of all submitters
Displaying the submitter´s press releases: Neovii Pharmaceuticals
Press releases found: 1
Long-term outcomes after standard graft-versus-host disease (GvHD) prophylaxis in hemopoietic cell transplantation from matched unrelated donors strongly support the use of Grafalon® (anti-human-T-lymphocyte immunoglobulin) as standard therapy
Submitter: Neovii Pharmaceuticals
Press releases found: 1